Leerink Partnrs Issues Optimistic Estimate for REGN Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Leerink Partnrs lifted their Q4 2024 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a research note issued to investors on Tuesday, January 28th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will earn $9.82 per share for the quarter, up from their prior forecast of $8.81. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $37.74 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' Q1 2025 earnings at $6.80 EPS and FY2025 earnings at $33.55 EPS.

Several other analysts also recently issued reports on REGN. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday. Finally, Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $10.10 during trading hours on Thursday, hitting $672.98. The company's stock had a trading volume of 943,776 shares, compared to its average volume of 888,384. The company has a market cap of $73.95 billion, a PE ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The business has a 50 day moving average price of $722.11 and a two-hundred day moving average price of $926.91. Regeneron Pharmaceuticals has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of REGN. Mizuho Securities USA LLC boosted its holdings in Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after acquiring an additional 51,162 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Simplify Asset Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock worth $10,082,000 after purchasing an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $1,334,000. Finally, Daiwa Securities Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 12.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company's stock valued at $21,428,000 after buying an additional 2,234 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.